Session: TPS01 - Impact of HEMT on Health Outcomes Across the Spectrum of Disease
TPS01.2- Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and ≥1 F508del allele: 96-week interim results from an open-label extension study